RPG Life Sciences has appointed Ashok Nair as Managing Director (Designate) beginning January 7, 2025, following the upcoming retirement of current MD Yugal Sikri. Sikri, who has helmed the company for over six years, is set to superannuate on April 30, 2025.
In a press statement on Saturday, the company informed that under Sikri’s leadership, the company recorded an impressive fourfold increase in EBITDA, with margins improving by 1,290 basis points. Additionally, PAT saw an eightfold increase with margin improvements of 1,180 basis points, while ROCE surged by 2,130 basis points and ROE by 1,670 basis points. These gains enabled RPG Life Sciences to become debt-free, facilitating modernization efforts and expansion at both manufacturing facilities, as well as securing resources for future growth.
The remarkable growth trajectory also saw RPG Life Sciences’ market capitalisation soar by nearly 15 times within five years, significantly outperforming the Sensex and BSE Healthcare Index. The company’s achievements were further recognised in Dun & Bradstreet’s ‘India’s Top 500 Value Creators 2023’ publication, highlighting RPG Life Sciences among India’s most influential corporate players.
Ashok Nair, an experienced leader in the healthcare and pharmaceutical sector with 39 years of expertise, will officially step into the role of Managing Director on May 1, 2025, following shareholder approval. Nair’s background includes strategic roles at notable companies such as Abbott, Torrent Pharma, Sun Pharma, and Cipla, covering sales, marketing, and product management. He previously served as Managing Director of Abbott Primary Care and more recently co-founded WatchYourHealth, a B2B healthtech startup. He has also advised private equity firms on healthcare matters and contributed to policy formulation in collaboration with industry bodies.
, RPG Lifescience_20241109130458_original_image_5.webp)
_20241112165650_original_image_21.webp)
